Treatment Options for Patients with Brain Metastatic Disease in HER2-Positive Breast Cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Treatment Options for Patients with Brain Metastatic Disease in HER2-Positive Breast Cancer ; volume:41 ; number:05 ; year:2020 ; pages:735-737
Indian journal of medical & paediatric oncology ; 41, Heft 05 (2020), 735-737
- Beteiligte Personen und Organisationen
-
Dhanushkodi, Manikandan
- DOI
-
10.4103/ijmpo.ijmpo_98_20
- URN
-
urn:nbn:de:101:1-2021082712032113111065
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Dhanushkodi, Manikandan
Ähnliche Objekte (12)
How We Treat HER2-Positive Metastatic Breast Cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer
Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer – a Danish register-based study from 2005 to 2016
New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
How We Treat HER2-Positive Metastatic Breast Cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer
Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer – a Danish register-based study from 2005 to 2016
New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
How We Treat HER2-Positive Metastatic Breast Cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer
Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer – a Danish register-based study from 2005 to 2016
New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte